GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Investments And Advances

Oruka Therapeutics (FRA:HQ1) Investments And Advances : €17.26 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Investments And Advances?

Oruka Therapeutics's Investments And Advances for the quarter that ended in Dec. 2024 was €17.26 Mil.

Oruka Therapeutics's quarterly Investments And Advances stayed the same from . 20 (€0.00 Mil) to . 20 (€0.00 Mil) but then increased from . 20 (€0.00 Mil) to Dec. 2024 (€17.26 Mil).

Oruka Therapeutics's annual Investments And Advances stayed the same from . 20 (€0.00 Mil) to . 20 (€0.00 Mil) but then increased from . 20 (€0.00 Mil) to Dec. 2024 (€17.26 Mil).


Oruka Therapeutics Investments And Advances Historical Data

The historical data trend for Oruka Therapeutics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Investments And Advances Chart

Oruka Therapeutics Annual Data
Trend Dec24
Investments And Advances
17.26

Oruka Therapeutics Semi-Annual Data
Dec24
Investments And Advances 17.26

Oruka Therapeutics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Oruka Therapeutics Business Description

Traded in Other Exchanges
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines